News for ETTX Stock

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022 Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc. Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference Innoviva to Acquire Entasis Therapeutics Innoviva to Acquire Entasis Therapeutics Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference Innoviva Reports First Quarter 2022 Financial Results Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc. Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022 Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021 Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update Entasis Therapeutics to Host Expert Perspectives Webinar on Acinetobacter Infections Entasis Therapeutics to Report Second Quarter 2021 Results and Host Conference Call August 12, 2021 Entasis Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference Entasis Therapeutics and Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial of Sulbactam-Durlobactam Entasis Therapeutics Expands Executive Leadership Team with the Appointment of Anna Diaz Triola as Chief Commercial Officer Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva Entasis Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S. Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update Entasis Therapeutics Highlights Multiple Data Presentations at Virtual ID Week Entasis Therapeutics to Participate in Upcoming Healthcare Investor Conferences Entasis Therapeutics Announces $25 Million Private Placement Entasis Therapeutics Awarded Contract from National Institutes of Health Entasis Therapeutics Reports First Quarter 2020 Financial Results and Business Update Entasis Therapeutics Completes Closing of Second Tranche of $35M Private Placement with Innoviva